Nearly 15 years after trying an experimental drug on children in Nigeria during a deadly meningitis epidemic, Pfizer Inc. is still battling the legal claims brought by the children’s families; the families are still waiting for some sort of compensation; and the case is still bogged down in pretrial motions.
But as the case drags along in Manhattan federal court, new developments are drawing more attention to it overseas.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
